Your browser doesn't support javascript.
loading
Pneumococcal Carriage in Burkina Faso After 13-Valent Pneumococcal Conjugate Vaccine Introduction: Results From 2 Cross-sectional Population-Based Surveys.
Kaboré, Lassané; Adebanjo, Tolulope; Njanpop-Lafourcade, Berthe Marie; Ouangraoua, Soumeya; Tarbangdo, Felix T; Meda, Bertrand; Velusamy, Srinivasan; Bicaba, Brice; Aké, Flavien; McGee, Lesley; Yaro, Seydou; Betsem, Edouard; Gervaix, Alain; Gessner, Bradford D; Whitney, Cynthia G; Moïsi, Jennifer C; Van Beneden, Chris A.
Afiliação
  • Kaboré L; Agence de Médecine Préventive, Ouagadougou, Burkina Faso.
  • Adebanjo T; Institute of Global Health, University of Geneva, Geneva, Switzerland.
  • Njanpop-Lafourcade BM; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Ouangraoua S; Agence de Médecine Préventive, Ouagadougou, Burkina Faso.
  • Tarbangdo FT; Centre Muraz, Bobo-Dioulasso, Burkina Faso.
  • Meda B; Davycas International, Ouagadougou, Burkina Faso.
  • Velusamy S; Agence de Médecine Préventive, Ouagadougou, Burkina Faso.
  • Bicaba B; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Aké F; Ministère de la Santé, Ouagadougou, Burkina Faso.
  • McGee L; Davycas International, Ouagadougou, Burkina Faso.
  • Yaro S; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Betsem E; Centre Muraz, Bobo-Dioulasso, Burkina Faso.
  • Gervaix A; Agence de Médecine Préventive, Ouagadougou, Burkina Faso.
  • Gessner BD; Pfizer, Paris, France.
  • Whitney CG; Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon.
  • Moïsi JC; Department of Pediatrics, University Hospitals of Geneva, Geneva, Switzerland.
  • Van Beneden CA; Agence de Médecine Préventive, Paris, France.
J Infect Dis ; 224(12 Suppl 2): S258-S266, 2021 09 01.
Article em En | MEDLINE | ID: mdl-34469552
BACKGROUND: Burkina Faso, a country in Africa's meningitis belt, introduced 13-valent pneumococcal conjugate vaccine (PCV13) in October 2013, with 3 primary doses given at 8, 12 and 16 weeks of age. To assess whether the new PCV13 program controlled pneumococcal carriage, we evaluated overall and serotype-specific colonization among children and adults during the first 3 years after introduction. METHODS: We conducted 2 population-based, cross-sectional, age-stratified surveys in 2015 and 2017 in the city of Bobo-Dioulasso. We used standardized questionnaires to collect sociodemographic, epidemiologic, and vaccination data. Consenting eligible participants provided nasopharyngeal (all ages) and oropharyngeal (≥5 years only) swab specimens. Swab specimens were plated onto blood agar either directly (2015) or after broth enrichment (2017). Pneumococci were serotyped by conventional multiplex polymerase chain reaction. We assessed vaccine effect by comparing the proportion of vaccine-type (VT) carriage among colonized individuals from a published baseline survey (2008) with each post-PCV survey. RESULTS: We recruited 992 (2015) and 1005 (2017) participants. Among children aged <5 years, 42.8% (2015) and 74.0% (2017) received ≥2 PCV13 doses. Among pneumococcal carriers aged <1 year, VT carriage declined from 55.8% in 2008 to 36.9% in 2017 (difference, 18.9%; 95% confidence interval, 1.9%-35.9%; P = .03); among carriers aged 1-4 years, VT carriage declined from 55.3% to 31.8% (difference, 23.5%; 6.8%-40.2%; P = .004); and among participants aged ≥5 years, no significant change was observed. CONCLUSION: Within 3 years of PCV13 implementation in Burkina Faso, we documented substantial reductions in the percentage of pneumococcal carriers with a VT among children aged <5 years, but not among persons aged ≥5 years. More time, a change in the PCV13 schedule, or both, may be needed to better control pneumococcal carriage in this setting.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND / 4_TD Base de dados: MEDLINE Assunto principal: Infecções Pneumocócicas / Streptococcus pneumoniae / Portador Sadio / Nasofaringe / Vacinas Conjugadas / Vacinas Pneumocócicas Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies / Screening_studies Limite: Child, preschool / Female / Humans / Infant / Male / Newborn País/Região como assunto: Africa Idioma: En Revista: J Infect Dis Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND / 4_TD Base de dados: MEDLINE Assunto principal: Infecções Pneumocócicas / Streptococcus pneumoniae / Portador Sadio / Nasofaringe / Vacinas Conjugadas / Vacinas Pneumocócicas Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies / Screening_studies Limite: Child, preschool / Female / Humans / Infant / Male / Newborn País/Região como assunto: Africa Idioma: En Revista: J Infect Dis Ano de publicação: 2021 Tipo de documento: Article